FDA Delay for REGENXBIO May Open the Door for Denali in Hunter Syndrome Race

A regulatory setback for REGENXBIO (NASDAQ: RGNX) is reshaping the competitive landscape in Hunter syndrome (MPS II), potentially giving Denali Therapeutics (NASDAQ: DNLI) a timing advantage as both companies move toward key FDA decisions in 2026.

The U.S. Food and Drug Administration recently placed a clinical hold on REGENXBIO’s gene therapy programs RGX-111 and RGX-121, following the identification of a tumor in a patient previously treated with RGX-111. While the case is still under investigation and no definitive causal link has been established, the agency cited potential shared risk across the platform, prompting a pause that introduces uncertainty around REGENXBIO’s regulatory timeline.

Why the Delay Matters

RGX-121, REGENXBIO’s investigational one-time gene therapy for Hunter syndrome, had been approaching a potential approval decision in early 2026. The clinical hold now clouds that outlook, creating the possibility of a delayed or extended review process.

For investors, the development highlights a familiar dynamic in gene therapy: even late-stage programs can face abrupt regulatory friction when long-term safety signals emerge. The resulting uncertainty weighed on RGNX shares as markets reassessed approval timing and risk.

Denali’s Differentiated Path

Against that backdrop, Denali Therapeutics appears increasingly well positioned. Denali’s Hunter syndrome candidate, tividenofusp alfa, is a fusion protein enzyme-replacement therapy designed to cross the blood–brain barrier and address both neurological and systemic aspects of the disease.

Importantly, Denali’s approach does not rely on viral gene delivery, which may allow it to sidestep the safety concerns now facing AAV-based gene therapies. Denali is currently awaiting an FDA decision with a PDUFA target date in April 2026, placing it on a potentially clearer regulatory path if no new issues arise.

From a competitive standpoint, this could allow Denali to emerge as the first approved therapy targeting the neurological manifestations of Hunter syndrome, a meaningful distinction in a disease with limited treatment options.

Investor Perspective

The divergence between the two programs underscores how mechanism of action and regulatory risk can rapidly alter competitive positioning in rare disease markets. While REGENXBIO’s gene therapy strategy offers the appeal of a one-time treatment, it also carries platform-level safety risk that can spill across programs.

Denali, by contrast, is advancing a more traditional — though technically sophisticated — biologic approach that may be viewed more favorably by regulators in the current environment. The company has already taken steps to prepare for commercialization, signaling confidence in its regulatory trajectory.

Bottom Line

REGENXBIO’s clinical hold has introduced a meaningful timing risk for RGX-121 and shifted investor focus toward Denali as a potential front-runner in the Hunter syndrome space. While outcomes for both programs remain uncertain, the latest FDA action highlights how quickly regulatory dynamics can change — and how differentiated approaches can become decisive in rare disease drug development.

For investors, attention now turns to Denali’s upcoming FDA decision and any updates from REGENXBIO regarding the resolution of its clinical hold, as both events are likely to drive further volatility and re-rating across the space.